Click Here for 5% Off Your First Aladdin Purchase!

CH5183284 (Debio-1347) - 99%, high purity , Fibroblast growth factor receptor 1 inhibitor, CAS No.1265229-25-1, Fibroblast growth factor receptor 1 inhibitor

  • Moligand™
  • ≥99%
Item Number
C302315
Grouped product items
SKUSizeAvailabilityPrice Qty
C302315-5mg
5mg
Available within 1-2 weeks(?)
Item is derived from our semi-finished stock and is processed in 1-2 weeks.
$48.90
C302315-10mg
10mg
In stock
$88.90
C302315-25mg
25mg
In stock
$187.90
C302315-50mg
50mg
In stock
$305.90
C302315-100mg
100mg
In stock
$494.90

Basic Description

Synonyms1265229-25-1|Debio-1347|CH5183284|zoligratinib|CH5183284 (Debio-1347)|CH-5183284|Debio 1347|FF284|(5-Amino-1-(2-methyl-1H-benzo[d]imidazol-6-yl)-1H-pyrazol-4-yl)(1H-indol-2-yl)methanone|NR9ZYH80Z8|CHEMBL3907479|Methanone, (5-amino-1-(2-methyl-1H-benzimida
Specifications & PurityMoligand™, ≥99%
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionFibroblast growth factor receptor 1 inhibitor

Product Properties

ALogP3.9

Names and Identifiers

Pubchem Sid488202056
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/488202056
IUPAC Name [5-amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone
INCHI InChI=1S/C20H16N6O/c1-11-23-16-7-6-13(9-17(16)24-11)26-20(21)14(10-22-26)19(27)18-8-12-4-2-3-5-15(12)25-18/h2-10,25H,21H2,1H3,(H,23,24)
InChi Key BEMNJULZEQTDJY-UHFFFAOYSA-N
Canonical SMILES CC1=NC2=C(N1)C=C(C=C2)N3C(=C(C=N3)C(=O)C4=CC5=CC=CC=C5N4)N
Isomeric SMILES CC1=NC2=C(N1)C=C(C=C2)N3C(=C(C=N3)C(=O)C4=CC5=CC=CC=C5N4)N
PubChem CID 66555680
Molecular Weight 356.38

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

10 results found

Lot NumberCertificate TypeDateItem
D23201051Certificate of AnalysisMar 27, 2023 C302315
D23201052Certificate of AnalysisMar 27, 2023 C302315
D23201061Certificate of AnalysisMar 27, 2023 C302315
D23201062Certificate of AnalysisMar 27, 2023 C302315
D23201066Certificate of AnalysisMar 27, 2023 C302315
D23201067Certificate of AnalysisMar 27, 2023 C302315
D23201069Certificate of AnalysisMar 27, 2023 C302315
D23201076Certificate of AnalysisMar 27, 2023 C302315
D2320526Certificate of AnalysisMar 27, 2023 C302315
D2320533Certificate of AnalysisMar 27, 2023 C302315

Related Documents

References

1. Nakanishi Y, Akiyama N, Tsukaguchi T, Fujii T, Sakata K, Sase H, Isobe T, Morikami K, Shindoh H, Mio T et al..  (2014)  The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor..  Mol Cancer Ther,  13  (11): (2547-58).  [PMID:25169980]
2. Voss MH, Hierro C, Heist RS, Cleary JM, Meric-Bernstam F, Tabernero J, Janku F, Gandhi L, Iafrate AJ, Borger DR et al..  (2019)  A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations..  Clin Cancer Res,  25  (9): (2699-2707).  [PMID:30745300]

Solution Calculators